Concepedia

Kyle W. Sloop

KW

79

Publications

6.2K

Citations

43

H-Index

1996

Active since

Affiliations

Eli Lilly (United States)(Current)

Indiana University – Purdue University Indianapolis

University of Indianapolis

Ionis Pharmaceuticals (United States)

University of Toronto

Kyle W. Sloop is an author at Eli Lilly (United States) specializing in medicine, endocrinology, and physiology.

ORCID

Top concepts

Publications per year

1996–2025

79

Publications

79

LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept

Tamer Coşkun, Kyle W. Sloop, Corina Loghin et al. · Molecular Metabolism · 2018 · 766 citations · Full text

Regulation of Expression of ob mRNA and Protein by Glucocorticoids and cAMP

Lawrence J. Slieker, Kyle W. Sloop, Peggy L. Surface et al. · Journal of Biological Chemistry · 1996 · 479 citations · Full text

Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist

Francis S. Willard, Jonathan D. Douros, M Gabe et al. · JCI Insight · 2020 · 439 citations · Full text

, , +20

LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept

Tamer Coşkun, Shweta Urva, William C. Roell et al. · Cell Metabolism · 2022 · 246 citations · Full text

Hepatic and glucagon-like peptide-1–mediated reversal of diabetes by glucagon receptor antisense oligonucleotide inhibitors

Kyle W. Sloop, Julia X.C. Cao, Angela M. Siesky et al. · Journal of Clinical Investigation · 2004 · 210 citations · Full text

Rows per page

1–5 of 79